Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)

Summary Background Limited data exist on transitioning patients with psoriasis from conventional systemic agents to biologics. Objectives The TRANSIT study aimed to assess the efficacy and safety of two methotrexate‐to‐ustekinumab transition strategies. Methods Patients with moderate‐to‐severe psori...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2014-02, Vol.170 (2), p.425-434
Hauptverfasser:	Paul, C., Puig, L., Kragballe, K., Luger, T., Lambert, J., Chimenti, S., Girolomoni, G., Nicolas, J.-F., Rizova, E., Lavie, F., Mistry, S., Bergmans, P., Barker, J., Reich, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Biological and medical sciences Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatology Dose-Response Relationship, Drug Drug Substitution Female Humans Immunotherapy Male Medical sciences Methotrexate Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Monoclonal antibodies Psoriasis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Safety Treatment Outcome Ustekinumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!